Anti-HER1 x Anti-HER3 Bispecific Antibody (IgG-IgG) is designed to be generated by crosslinking two full length IgGs, anti-HER1 and anti-HER3 parental antibodies. A stable linkage is formed between the two antibodies. This BsAb can bind and inactivate two receptors simultaneously. It is designed for the research of Head and neck cancer; Colorectal cancer therapy.
There are currently no customer reviews or questions for Anti-HER1 x Anti-HER3 Bispecific Antibody (IgG-IgG) (BSIG-165). Click the button below to contact us or submit your feedback about this product.
Welcome! For price inquiries, we will get back to you as soon as possible.
INQUIRYSERVICES
PRODUCTS
PLATFORMS